Clinical Trial Update: Effects of Pioglitazone Treatment on Sympathetic Nervous System Function in Metabolic Syndrome Obesity [Phase 3]

View source ↗

Summary

A Phase 3 trial is evaluating pioglitazone for metabolic syndrome with obesity. The current status of the study is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Metabolic Syndrome
• Obesity

Drugs mentioned

• PIOGLITAZONE (Pioglitazone)

Snippet

Sponsor: Baker Heart Research Institute | Conditions: Metabolic Syndrome | Phase 3 | Status: UNKNOWN